Laura Stoppel
Person ● Covered in 0 stories + Follow ✴ AI Graph Request update
Laura Stoppel, PhD, is a board member at Nimbus Therapeutics and a Principal on the investment team at RA Capital Management. At RA Capital, she works on both public and private investments. Previously, she covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. She is also listed as a board director for Artiva Biotherapeutics and Acumen Pharmaceuticals and as a board observer for Vor Biopharma, and she holds a BA in biology and psychology from Harvard University and a PhD in neuroscience from MIT, where her graduate research investigated synaptic translation in syndromic autism.
Updated 19 October 2026
Public sources: nimbustx.com
Why this page exists, and how to correct or remove it
This profile is assembled automatically because Laura Stoppel appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.
We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.
Claim or correct this profile Request removal How we handle personal data